National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2017 (No. 9) (PB 94 of 2017) (Cth)

PB 94 of 2017

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2017 (No. 9)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated         28^th November 2017

LISA LA RANCE

Assistant Secretary

Pricing and Policy Branch

Technology Assessment and Access Division

Department of Health

___________________________________________________________________________

Amendment instrument – Pharmaceutical benefits – early supply

1          Name of Instrument

(1)      This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2017 (No. 9)

(2)This Instrument may also be cited as PB 94 of 2017.

2          Commencement

This Instrument commences on 1 December 2017.

3          Amendment of PB 120 of 2015

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

Schedule 1        Amendments

1. Schedule 1, after entry for Abiraterone

insert:

Abiraterone Tablet containing abiraterone acetate 500 mg 20 60 2

1. Schedule 1, entry for Atorvastatin and ezetimibe

omit:

Atorvastatin and ezetimibe	Pack containing 30 tablets atorvastatin 10 mg (as calcium) and 30 tablets ezetimibe 10 mg	20	1	5
Atorvastatin and ezetimibe	Pack containing 30 tablets atorvastatin 20 mg (as calcium) and 30 tablets ezetimibe 10 mg	20	1	5
Atorvastatin and ezetimibe	Pack containing 30 tablets atorvastatin 40 mg (as calcium) and 30 tablets ezetimibe 10 mg	20	1	5
Atorvastatin and ezetimibe	Pack containing 30 tablets atorvastatin 80 mg (as calcium) and 30 tablets ezetimibe 10 mg	20	1	5

1. Schedule 1, entry for Auranofin

omit:

Auranofin Tablet 3 mg 20 100 3

1. Schedule 1, after entry for Ibandronic acid

insert:

Ibrutinib Capsule 140 mg 20 90 5

1. Schedule 1, after entry for Mesalazine in the form Tablet 500 mg (prolonged release)

insert:

Mesalazine Tablet 800 mg (enteric coated) 20 180 5

1. Schedule 1, entry for Tenofovir with emtricitabine, elvitegravir and cobicistat

omit:

Tenofovir with emtricitabine, elvitegravir and cobicistat Tablet containing tenofovir alafenamide 10 mg with emtricitabine 200 mg, elvitegravir 150 mg and cobicistat 150 mg 20 60 5

1. Schedule 1, after entry for Umeclidinium with vilanterol

insert:

Ustekinumab Injection 45 mg in 0.5 mL 20 1 1